Strides Pharma Science Limited is pleased to announce that Aditya Puri joins the Strides Group as an Advisor and also will be a Director of its associate Company, Stelis Biopharma.
New digital platform provides global sponsors with live visibility into R&D, process development and GMP manufacturing operations, enhancing collaboration and decision-making
The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines
The company reported consolidated revenue of Rs. 172.9 crore and EBITDA of Rs 25.9 crore in FY26
As per union government, growing public participation reflects rising awareness and collective commitment towards advancing organ and tissue donation
Initiative seeks innovative experimental and computational approaches to uncover neural circuits regulating immune function and identify novel therapeutic targets
The company said the safety profile remained consistent with earlier studies and was considered manageable
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
The backing comes as influenza remains a persistent public health burden
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
